Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Receivables (2016 - 2025)

CytomX Therapeutics' Receivables history spans 12 years, with the latest figure at $2.9 million for Q4 2025.

  • For Q4 2025, Receivables fell 30.69% year-over-year to $2.9 million; the TTM value through Dec 2025 reached $2.9 million, down 30.69%, while the annual FY2025 figure was $2.9 million, 30.69% down from the prior year.
  • Receivables reached $2.9 million in Q4 2025 per CTMX's latest filing, up from $2.7 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $71.0 million in Q4 2022 to a low of $1.6 million in Q1 2021.
  • Average Receivables over 5 years is $7.5 million, with a median of $3.0 million recorded in 2025.
  • Peak YoY movement for Receivables: crashed 99.26% in 2021, then soared 4364.53% in 2022.
  • A 5-year view of Receivables shows it stood at $1.6 million in 2021, then skyrocketed by 4364.53% to $71.0 million in 2022, then tumbled by 92.07% to $5.6 million in 2023, then fell by 25.37% to $4.2 million in 2024, then tumbled by 30.69% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Receivables are $2.9 million (Q4 2025), $2.7 million (Q3 2025), and $3.1 million (Q2 2025).